Minutia develops transplantable insulin‑producing cell clusters that embed nanoscale sensors for continuous in‑vivo monitoring of graft function. The integrated bioelectronic platform provides real‑time data on insulin secretion and cell viability, enabling clinicians to adjust therapy promptly and improve long‑term glycemic control for diabetes patients.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with diabetes lack a durable, controllable source of insulin-producing cells, and current cell transplant therapies cannot be monitored in real time, limiting safety and efficacy assessments.
Solution
Minutia is developing transplantable insulin-producing cell clusters that incorporate nanoscale sensors to enable continuous in vivo monitoring of graft function. The integrated sensors provide real-time data on insulin secretion and cell viability, allowing clinicians to adjust therapy promptly and reduce the risk of graft failure. By engineering more robust cell constructs, Minutia aims to improve long-term glycemic control and reduce the need for frequent exogenous insulin administration. The platform combines advanced cell engineering with bioelectronic monitoring to create a closed-loop cell therapy solution for diabetes.
Target Audience
Primary customers are endocrinologists, diabetes care centers, and biotech firms developing cell-based therapies for type 1 and advanced type 2 diabetes.
Features
- Engineered insulin-producing cell aggregates designed for enhanced survival and function after transplantation
- Embedded nanosensors that continuously report insulin output and cellular health metrics
- Wireless data transmission to a secure cloud platform for real-time clinician access
- Compatibility with minimally invasive implantation techniques
- Scalable manufacturing process for consistent cell product quality